The Future of Pain Pharmacotherapy



Fig. 19.1
A hypothetical graph of the number of available drugs as a function of time. The scales on the abscissa and ordinate are deliberately not specified (See text for discussion)





Summary/Conclusions


Despite efforts to maximize the utility of existing pain medicines, obvious shortfalls in the analgesic armamentarium persist. Analgesics based upon novel molecular and genetic mechanisms are being intensively explored to address the unmet needs of patients in pain [42]. The discovery and development of such medicines may require a surprising amount of effort and expense, however, to progress only slightly up the curve shown in Fig. 19.1. To some degree, this slowness to progress may reflect the many late-stage failures among recently developed analgesic compounds due to an unintended negative bias in the current FDA drug approval framework, such as overlooking subgroups of responders [46]. Further, on a global scale, many of the analgesic gaps between ideal and actual practice may be addressed simply by providing access to simple inexpensive agents such as anti-inflammatory drugs or opioids [47]. Nonetheless, even after taking these factors under consideration, it is safe to predict that in the wealthier nations, the search for new analgesics with an improved effect to side-effect profile and improved methods for the delivery of familiar agents will continue for some time to come.


Acknowledgment

Partial support for this work was provided by the Saltonstall Fund for Pain Research.


References



1.

Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education and research. Washington D.C.: The National Academies Press; 2011.


2.

Coggeshall RE, Carlton SM. Receptor localization in the mammalian dorsal horn and primary afferent neurons. Brain Res Rev. 1997;24:28–66.PubMedCrossRef


3.

Traub RJ. The spinal contribution of the induction of central sensitization. Brain Res. 1997;778:34–42.PubMedCrossRef


4.

Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth. 1995;75:193–200.PubMedCrossRef


5.

Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5(Suppl):1062–7.PubMedCrossRef


6.

Rittner HL, Brack A, Machelska H, et al. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology. 2001;95:500–8.PubMedCrossRef


7.

Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57:1–164.PubMedCrossRef


8.

Machelska H, Stein C. Immune mechanisms in pain control. Anesth Analg. 2002;95:1002–8.PubMed


9.

Shu X-Q, Mendell LM. Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A. 1999;96:7693–6.PubMedCentralPubMedCrossRef


10.

Thompson SWN, Bennett DLH, Kerr BJ, Bradbury EJ, McMahon SB. Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci U S A. 1999;96:7714–8.PubMedCentralPubMedCrossRef


11.

Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1: an update. Eur J Biochem. 2004;271:1814–9.PubMedCrossRef


12.

Rashid MH, Inoune M, Kondo S, Kawashima T, Bakoshi S, Ueda H. Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther. 2003;304:940–8.PubMedCrossRef

Oct 21, 2016 | Posted by in PAIN MEDICINE | Comments Off on The Future of Pain Pharmacotherapy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access